• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

ViroPharma Sinks After FDA Denies Vancocin Exclusivity

April 11, 2012
By Marie Powers
Shares of ViroPharma Inc. were rocked Tuesday after the FDA informed the company that the supplemental new drug application (sNDA) for its antibiotic Vancocin (vancomycin hydrochloride), approved in December 2011, would not qualify for three additional years of exclusivity.
Read More

HIG Capital closes a new $268M life sciences fund

April 10, 2012
By Marie Powers
In another sign that the venture financing market may be stirring from its long recession nap, HIG Capital (Miami) closed a new life sciences fund, HIG BioVentures II LLP, with commitments of $268 million, exceeding its $250 million target.
Read More

HIG Capital Closes New $268M Life Sciences Fund

April 10, 2012
By Marie Powers
In another sign that the venture financing market may be stirring from its long recession nap, HIG Capital LLC closed a new life sciences fund, HIG BioVentures II LLP, with commitments of $268 million, exceeding its $250 million target.
Read More

OvaScience Aims to Reshape IVF Using Egg Precursor Cells

April 6, 2012
By Marie Powers
Privately held OvaScience has burst onto the infertility scene in a big way, raising $43 million since its founding in 2011, including a $37 million Series B round that closed this week.
Read More

Clovis Follows 2011 IPO with $75M Public Offering

April 5, 2012
By Marie Powers
Clovis Oncology Inc. wasted little time padding its coffers after an initial public offering (IPO) in November 2011 put the small biopharma in a category of one: Clovis was the only biotech to price a 2011 IPO within its initial range.
Read More

ThromboGenics Extends Runway with $103.2M Raise

April 4, 2012
By Marie Powers
Ten days after inking a potential $494 million deal with eye care specialist Alcon Inc. for the ex-U.S. rights to vitreous macular adhesion (VMA) candidate ocriplasmin, ThromboGenics NV raised €77.8 million (US$103.2 million) in a private placement of about 3.2 million new shares with domestic and international investors.
Read More

Stemline Therapeutics Follows Verastem's Lead, Files for IPO

April 4, 2012
By Marie Powers
Following the lead of Verastem Inc., which raised $55 million earlier this year in its initial public offering (IPO), New York-based Stemline Therapeutics Inc. filed an S-1 registration statement with the SEC for an IPO, seeking $50 million to advance its cancer stem cell therapeutics.
Read More

ThromboGenics Extends Runway with $103.2M Raise

March 30, 2012
By Marie Powers
Ten days after inking a potential $494 million deal with eye care specialist Alcon Inc. for the ex-U.S. rights to vitreous macular adhesion (VMA) candidate ocriplasmin, ThromboGenics NV raised €77.8 million (US$103.2 million) in a private placement of 3,244,677 new shares with domestic and international investors.
Read More

Cytos' $40.6M Financing Gives Asthma Drug Breathing Room

March 28, 2012
By Marie Powers
Switzerland's Cytos Biotechnology Ltd. stepped away from the ledge of a financial precipice last week and rescued its lead immunodrug candidate CYT003-QbG10 by forging agreements with a syndicate of international investors to raise up to CHF37 million (US$40.6 million) in equity and debt.
Read More

Tesaro Files for $86M IPO to Advance CINV Drug Rolapitant

March 27, 2012
By Marie Powers
Tesaro Inc. continued its stellar trajectory, filing an S-1 registration statement with the SEC seeking to raise up to $86.3 million in an initial public offering (IPO) to advance rolapitant, its selective neurokinin-1 (NK1) receptor antagonist with an extended plasma half-life.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • Deal handshake with coin, chart background

    Shionogi to acquire Japan Tobacco pharma companies for $1.1B

    BioWorld
    Shionogi & Co. said it plans to acquire Japan Tobacco Inc. (JT) subsidiaries Torii Pharmaceutical Co. and Akros Pharma Inc. for ¥160 billion (US$1.1 billion) to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe